Farletuzumab ELISA Kit (DB825018)

Overview
Images
References
Datasheet

Overview

Catalog No.	DB825018
Description	Farletuzumab ELISA Kit (DB825018) — Quantitative sandwich ELISA for Farletuzumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml. Highlights ●Sandwich Format — High specificity, reliable quantification. ●High Sensitivity — Optimized for low-abundance target detection. ●Ready-to-Use — Complete kit with pre-coated plates included.
Sample type	Plasma, Serum
Sensitivity	0.156 μg/ml
Range	0.31-5 μg/mL
Accession	P15328
Applications	ELISA
Detection method	Colorimetric
Assay type	Quantitative
Recovery	80-120%
Shipping	2-8 ℃
Stability and Storage	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Specifications	Farletuzumab
Alternate Names	M3, MORAb-003, MORAb-003-VCP-eribulin, MORAb-202, 896723-44-7
Background	Folate receptor alpha (Farletuzumab) is a ~29 kDa protein. Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analogs at neutral pH. Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release. Required for normal embryonic development and normal cell proliferation. 1. Zhao, R. et al. (2009) The Journal of biological chemistry 284, 4267-74. PMID: 19074442 2. Chen, C. et al. (2013) Nature 500, 486-9. PMID: 23851396 3. Wibowo, AS. et al. (2013) Proceedings of the National Academy of Sciences of the United States of America 110, 15180-8. PMID: 23934049 4. Lacey, SW. et al. (1989) The Journal of clinical investigation 84, 715-20. PMID: 2527252 5. Orr, RB. et al. (1994) Cancer research 54, 3905-11. PMID: 8033114 6. Rijnboutt, S. et al. (1996) The Journal of cell biology 132, 35-47. PMID: 8567728
Note	For Research Use Only.